Nerea Lopetegui-Lia, MD

Experts share vital insights on managing HR-positive breast cancer, emphasizing education, patient quality of life, and the evolving landscape of therapies.

Engaging Long-Term HR Positive Metastatic Patients in Shared Decision Making

Clinicians explore essential pre-treatment assessments and monitoring strategies to manage toxicities from new cancer therapies effectively.

Early intervention in cancer treatment aims to enhance patient quality of life and longevity, balancing therapy effectiveness with individual needs.

Experts discuss the evolving landscape of breast cancer treatment, emphasizing the importance of ctDNA testing for personalized therapy decisions.

Experts discuss balancing efficacy and quality of life in SERD therapies, highlighting unique toxicities and the importance of patient education.

Early detection of ESR1 mutations in breast cancer enhances treatment strategies, potentially improving patient outcomes and quality of life.

Clinicians explore the differences between EMERALD and EMBER3 trials, focusing on patient characteristics, treatment efficacy, and future therapy roles.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Oral SERDs emerge as a standard treatment for HR-positive, HER2-negative metastatic breast cancer, especially for patients with ESR1 mutations.

Experts discuss the impact of biomarkers and treatment duration on decision-making for CDK4/6 inhibitors in breast cancer adjuvant therapy.

Discover effective strategies for managing toxicities in patients using CDK4/6 inhibitors, ensuring adherence and optimal treatment outcomes.

Clinicians explore barriers to adjuvant CDK4/6-inhibitor therapy, emphasizing education and streamlined communication to improve patient outcomes.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

Experts discuss advancements in HR-positive breast cancer treatment, focusing on CDK4/6 inhibitors, SERDs, and early intervention strategies.

CDK4/6 Inhibition in HR-Positive Breast Cancer: Evolving Standards in Early and Metastatic Care

Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.

Nerea Lopetegui-Lia, MD, discusses treatment options for patients with chemotherapy-pretreated early-stage high-risk TNBC with residual disease at surgery.